Intersect ENT Inc (NASDAQ:XENT) has been assigned a consensus rating of “Buy” from the eleven research firms that are covering the company. Three analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $19.20.
XENT has been the subject of a number of recent analyst reports. Northland Securities reaffirmed a “buy” rating and set a $17.00 price target on shares of Intersect ENT in a report on Monday, March 13th. Canaccord Genuity initiated coverage on Intersect ENT in a report on Wednesday, March 8th. They set a “buy” rating and a $17.00 price target for the company. Deutsche Bank AG raised Intersect ENT from a “hold” rating to a “buy” rating and raised their price target for the company from $15.00 to $19.00 in a report on Monday, March 6th. Guggenheim initiated coverage on Intersect ENT in a report on Tuesday, December 6th. They set a “buy” rating and a $20.00 price target for the company. Finally, Wedbush reaffirmed an “outperform” rating and set a $25.00 price target on shares of Intersect ENT in a report on Wednesday, January 11th.
Your IP Address:
Shares of Intersect ENT (NASDAQ:XENT) opened at 16.40 on Thursday. Intersect ENT has a one year low of $7.65 and a one year high of $20.64. The stock’s 50 day moving average price is $13.86 and its 200 day moving average price is $13.56. The stock’s market capitalization is $470.30 million.
Intersect ENT (NASDAQ:XENT) last released its quarterly earnings results on Tuesday, February 28th. The company reported ($0.17) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.03. Intersect ENT had a negative return on equity of 21.25% and a negative net margin of 35.69%. The firm earned $24.20 million during the quarter, compared to analysts’ expectations of $23.47 million. During the same period last year, the firm posted ($0.20) EPS. The business’s revenue was up 28.7% on a year-over-year basis. On average, analysts forecast that Intersect ENT will post ($0.79) EPS for the current year.
In other news, insider Lisa D. Earnhardt sold 20,000 shares of Intersect ENT stock in a transaction on Wednesday, March 15th. The stock was sold at an average price of $15.02, for a total value of $300,400.00. Following the completion of the sale, the insider now directly owns 620,868 shares of the company’s stock, valued at approximately $9,325,437.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 13.90% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada boosted its stake in Intersect ENT by 46,250.0% in the second quarter. Royal Bank of Canada now owns 46,350 shares of the company’s stock valued at $599,000 after buying an additional 46,250 shares during the period. Wells Fargo & Company MN boosted its stake in Intersect ENT by 7.8% in the third quarter. Wells Fargo & Company MN now owns 103,909 shares of the company’s stock valued at $1,646,000 after buying an additional 7,516 shares during the period. Mutual of America Capital Management LLC boosted its stake in Intersect ENT by 21.4% in the third quarter. Mutual of America Capital Management LLC now owns 111,311 shares of the company’s stock valued at $1,763,000 after buying an additional 19,600 shares during the period. CAM Group Holding A S purchased a new stake in Intersect ENT during the third quarter valued at approximately $2,614,000. Finally, Tiverton Asset Management LLC purchased a new stake in Intersect ENT during the third quarter valued at approximately $1,188,000. 77.81% of the stock is owned by institutional investors.
About Intersect ENT
Intersect ENT, Inc is a commercial stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. It has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. Its commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis.
Receive News & Ratings for Intersect ENT Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc and related companies with MarketBeat.com's FREE daily email newsletter.